Indication
Metastatic Hormone Receptor-Positive Breast Carcinoma
3 clinical trials
10 products
2 drugs
Clinical trial
A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Product
AbemaciclibProduct
AnastrozoleProduct
ExemestaneProduct
FulvestrantProduct
LetrozoleDrug
TamoxifenProduct
EstradiolClinical trial
Phase 2 Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Inactivating or Inferred Inactivating NF1 Alterations: A ComboMATCH Treatment TrialStatus: Recruiting, Estimated PCD: 2026-11-01
Product
BinimetinibDrug
AlpelisibClinical trial
A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination With Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine-Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)Status: Active (not recruiting), Estimated PCD: 2023-06-22
Product
Copanlisib